The Three Unmet Needs Defining Treatment of HS
~20% of Dupixent-treated atopic dermatitis patients are refractory to the drug (MARKETVUE® REPORT)
While non-response to Dupixent is uncommon, atopic dermatitis (AD) patients who are refractory lack safe and effective treatments. NEWTON, Mass., July 26, 2023 /PRNewswire/ -- Atopic dermatitis (AD) is a chronic, inflammatory [...]
Spevigo launch going well for Generalized Pustular Psoriasis (MARKETVUE® REPORT)
Boehringer-Ingelheim's intravenous Spevigo (spesolimab) is a therapy specifically indicated to treat active Generalized Pustular Psoriasis (GPP) flares. Nearly 90% of dermatologists with prior use reported spesolimab as very effective, according [...]
1 in 3 pemphigoid patients not well-managed on current treatments (MARKETVUE® REPORT)
Several companies including argenx, Sanofi/Regeneron, and AstraZeneca are seeking to improve Bullous Pemphigoid standard of care by pursuing label expansions for their existing antibody-based therapies. NEWTON, Mass., March 16, 2023 /PRNewswire/ -- Bullous [...]
MARKETVUE® REPORT: Frontal Fibrosing Alopecia burden of disease is significant with half of patients unable to achieve complete response to treatment
According to REACH Market Research, dermatologists agree that Frontal Fibrosing Alopecia (FFA) is generally more difficult to treat, and less likely to have an optimal response to treatment than Alopecia Areata [...]